Results 81 to 90 of about 2,675,009 (295)

Ruptured intracranial aneurysms: the overall effect of treatment and the influence of patient selection and data presentation on the reported outcome. [PDF]

, 1985
R. S. Maurice‐Williams, Henry Marsh
openalex   +1 more source

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

Molecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti, Manuel Scimeca, Julia Bischof, Jonathan Woodsmith, Massimiliano Agostini, Cristina Fiorani, Yufang Shi, Eleonora Candi, Gerry Melino, Alessandro Mauriello, Giuseppe S. Sica   +10 more
wiley   +1 more source

Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). [PDF]

, 2014
This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III).
Admani, S, Aoki, V, Apfelbacher, C, Ardeleanu, M, Barbarot, S, Berger, T, Bergman, JN, Block, J, Borok, N, Burton, T, Chalmers, JR, Chamlin, SL, Deckert, S, DeKlotz, CC, Dohil, M, Eichenfield, LF, Graff, LB, Hanifin, JM, Hebert, AA, Humphreys, R, Katoh, N, Kisa, RM, Margolis, DJ, Merhand, S, Minnillo, R, Mizutani, H, Nankervis, H, Ohya, Y, Rodgers, P, Schmitt, J, Schram, ME, Simpson, EL, Singh, J, Spuls, P, Stalder, JF, Svensson, A, Takaoka, R, Teper, A, Thomas, KS, Tom, WL, von Kobyletzki, L, Weisshaar, E, Williams, HC, Zelt, S   +43 more
core   +1 more source

On-line Medical Command and Patient-Initiated Refusals of Prehospital Care: Patient Outcome and Ambulance Call Report Documentation [PDF]

, 1993
David C. Cone, D.T Kim, S.J. Davidson
openalex   +1 more source

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes [PDF]

, 2009
To our knowledge, no comprehensive, interdisciplinary initiatives have been taken to examine the role of genetic variants on patient-reported quality-of-life outcomes.
Ailko H. Zwinderman, Amy P. Abertnethy, Amylou C. Dueck, Andrea M. Barsevick, Benjamin Movsas, Bower J. E., Cella D. F., Charles S. Cleeland, Christine Miaskowski, Cornelis J. F. Van Noorden, Cynthia Chauhan, Donald L. Patrick, Dorret I. Boomsma, Frank Baas, Gen Shinozaki, Jasvinder A. Singh, Jeff A. Sloan, Johnson W., Marlene H. Frost, Mary E. Ropka, Meike Bartels, Michele Y. Halyard, Miriam Mosing, Mirjam A. G. Sprangers, Mock V., Nancy L. Pedersen, Nicholas G. Martin, Per Hall, Ping Yang, Pål Klepstad, Quiling Shi, Rich T. A., Romeis J. C., Ruut Veenhoven, Svardh C., Svedberg P., Svedberg P., Yang P.   +37 more
core   +5 more sources

Differences in patient-reported processes and outcomes between men and women with myocardial infarction [PDF]

, 2000
Kenneth E. Covinsky, Mary‐Margaret Chren, Dwain L. Harper, Lynne E. Way, Gary E. Rosenthal   +4 more
openalex   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Pregnancy outcome in a patient with chronic malnutrition: Case report [PDF]

, 2000
Michael P. O’Connell, Oriole Wilson, E. A. Masson, Stephen W. Lindow   +3 more
openalex   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source